Open Access
Hepatitis B virus seroprevalence, associated factors and vaccination status among children and adolescents in Black Sea Region of Turkey
Erhan Karaaslan1*, Meryem Çetin2
1Tokat Gaziosmanpaşa University, Tokat, Turkey
2Tokat Gaziosmanpaşa University, Tokat, Turkey
* Corresponding author:

Presented at the 4th International Symposium on Innovative Approaches in Health and Sports Sciences (ISAS WINTER-2019 (HSS)), Samsun, Turkey, Nov 22, 2019

SETSCI Conference Proceedings, 2019, 12, Page (s): 87-91 ,

Published Date: 23 December 2019    | 723     20


The aim of this study was to determine the prevalence of hepatitis B virus (HBV) serologic markers in children and adolescents and the impact of the vaccination program over the last 9 years. The laboratory records of 10175 children were retrospectively evaluated in children who visited a tertiary hospital, between January 2009 and December 2017. The overall prevalence of HBsAg and anti-HBs were 2.0%, and 69.3%, respectively. HBsAg prevalence increased with age. The carriage rate was more prevalent  in rural areas and in cases born before the country-wide vaccination program. HBeAg positive cases were more common than anti-HBe Ag positive cases (67.6% vs. 32.4%). Anti-HBs was on a rising trend in the 1-23-month age group while it tended to decline after 2-6 years’ age group. There was a decrease in the prevalence of HBsAg in children due to ongoing vaccination efforts but the prevalence of HBsAg was still high during adolescence. The rates of anti-HBs positivity were lower in those living in rural areas and those born before the vaccination program.  Anti-HBs rates were decreasing as age progressed, but this decline was probably due to a natural reduction in anti-HBs concentration in successfully vaccinated individuals.  

Keywords - Hepatitis B, epidemiology, children, vaccination, Turkey


1. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: New estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30:2212-2219.
2. Lozano R, Naghavi M, Foreman K et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. The Lancet. 2012;380:2095-2128.
3. Liaw Y-F, Chu C-M. Hepatitis B virus infection. The Lancet. 2009;373:582-592.
4. Tosun S. Türkiye’de Viral Hepatit Epidemiyolojisi Yayınlarının Metanalizi. In: Tabak F, Tosun S, editors. Viral Hepatit 2013. Viral Hepatit Savaşım Derneği Istanbul: Istanbul Medikal Yayıncılık; 2013. p. 21-80.
5. Ertekin V, Selimoglu MA, Altınkaynak S. Sero-epidemiology of hepatitis B infection in an urban paediatric population in Turkey. Public Health. 2003;117:49-53.
6. Erden S, Büyüköztürk S, Calangu S, Yilmaz G, Palanduz S, Badur S. A study of serological markers of hepatitis B and C viruses in Istanbul, Turkey. Medical principles and practice : international journal of the Kuwait University, Health Science Centre. 2003;12:184-188.
7. Mehmet D, Meliksah E, Serif Y, Gunay S, Tuncer O, Zeynep S. Prevalence of hepatitis B infection in the southeastern region of Turkey: comparison of risk factors for HBV infection in rural and urban areas. Jpn J Infect Dis. 2005;58:15-19.
8. Hadziyannis SJ. Natural history of chronic hepatitis B in Euro-Mediterranean and African Countries. Journal of Hepatology. 2011;55:183-191.
9. Akarca US. Chronic hepatitis B. A guideline to diagnosis, approach, management, and follow-up 2007. Turkish Association for the Study of Liver. Turk J Gastroenterol. 2008;19:207-230.
10. Dentinger CM, McMahon BJ, Butler JC et al. Persistence of Antibody to Hepatitis B and Protection From Disease Among Alaska Natives Immunized at Birth. The Pediatric Infectious Disease Journal. 2005;24:786-792.

Copyright © 2024 SETECH
Tokat Technology Development Zone Gaziosmanpaşa University Taşlıçiftlik Campus, 60240 TOKAT-TÜRKİYE